All news articles

MS patient reports severe pain amid UK-wide nabilone shortage

A UK-wide nabilone shortage has left a woman with multiple sclerosis in severe pain, she told the BBC. The manufacturer hopes supplies will reach patients by mid-December, but that timetable is not confirmed.

AI-generated editorial illustration based on the published article topic; not a documentary photograph.
Loading statistics…

Review information is loading.

A UK-wide shortage of nabilone, a medicine Jill Kenning says helps control pain linked to her multiple sclerosis, has left her struggling after she ran out. Northern Ireland’s Department of Health says both licensed strengths are out of stock with UK wholesalers; the manufacturer hopes supplies will return in December, but has not confirmed that date.

Kenning, from Coleraine, told the BBC she had used nabilone for 17 of the 18 years since her MS diagnosis. She said that without it she had constant pain in her eye, which felt “like being stabbed with a hot poker”, and had spent most of her time in bed since running out the previous Tuesday.

After she contacted her health trust for a repeat prescription, Kenning said she was told there was no supply and advised to contact her neurologist. She has since been prescribed other medication, but said it had not worked and that her health had worsened to the point that she spent several nights in hospital. She told the BBC she could not sleep, was sick and was not eating.

The Department of Health said the shortage first affected 1mg capsules in July and later affected the 0.25mg strength. It said it was working with the UK Department of Health and Social Care and health trusts, and that healthcare professionals had been given guidance on alternatives, including unlicensed imports where available.

A supply notice issued on 14 July said 1mg capsules were out of stock, with resupply expected by the end of August, while 0.25mg capsules remained available at that time. The notice also said unlicensed imports of 1mg capsules could be sourced, with variable lead times. It is not an update on the wholesale position in October.

Brown & Burk UK, which supplies the drug, told the BBC that technical problems had forced it to manufacture the active ingredient again. Managing director Preetham Hiremat said the company hoped to get stock into the UK by the end of November and for it to reach users by mid-December. Those are the manufacturer’s projected dates, not a confirmed return to supply.

The department advised patients who cannot obtain their prescribed medicine, or who have concerns about an alternative, to speak to their specialist healthcare team.

Sign in to give this article a thumbs up or down.

From the discussion

Private test discussion. Comments are readers’ views and are not yet automatically fact-checked. Editing is available for 60 seconds after posting.

Sign in with a confirmed reader account and choose a username to read comments and participate.

Sorting applies to top-level comments; replies remain oldest first. New comments and likes can change the order. Refresh for the current ranking.

Loading comments…